Reroute is a smartphone-based digital therapeutic that turns the unmanaged time between clinical appointments into active, measurable neurological rehabilitation — using a device the patient already owns.
A patient can walk well in a corridor with a physiotherapist beside them, and freeze at a supermarket doorway three days later. The technique wasn't wrong — the support simply wasn't there when it mattered.
Movement strategies are highly context-dependent. Without supervision, cueing or feedback, they degrade in exactly the environments where symptoms actually occur.
The market is full of monitoring tools and wellness apps. Very few are true movement-retraining systems that intervene in the moment.
Most digital rehab requires dedicated wearables or clinic equipment — adding cost, friction and a procurement barrier that stops products reaching scale.
Decisions are made from sparse snapshots in clinic. What happens in the other 99% of a patient's week is invisible.
Most solutions solve one part of the problem — cueing, or tracking, or gamified rehab. Reroute integrates sensing, interpretation and intervention into a continuous real-time loop that adapts during the symptom itself.
The phone delivers rhythmic vibration that responds to how the person is actually moving — not a fixed metronome. Cue timing adapts to the individual moment, supporting gait initiation and breaking freezing episodes.
Built-in smartphone sensors convert ordinary walking into clinically interpretable data — cadence, symmetry, variability, freezing events — with no wearable, no setup and no conscious effort from the patient.
Light game layers pull conscious attention away from the movement itself — the mechanism that helps interrupt maladaptive patterns in Functional Neurological Disorder. Implicit retraining, not instruction.
Want to feel it rather than read it? Open the interactive demo — best on a phone, where the haptics and motion sensing are real.
Real-world data is translated into decision-ready insight — adherence, deviation, improvement — so the next consultation starts from evidence rather than recall. The dashboard highlights what changed, not everything that happened.
Sensing informs cueing. Cueing changes movement. Changed movement is sensed again. Each pass makes the intervention more personal — and every pass is recorded. That combination, not any single feature, is what competitors don't have.
We are not building a wellness app that gestures at neurology. We are building a regulated digital therapeutic — and the way we work reflects that.
Adoption runs through neurologists, physiotherapists and movement disorder specialists — never through app-store marketing. We start with a narrow clinical wedge in specialist neurorehabilitation, earn endorsement at the gatekeeper level, and let evidence do the selling inside the institution.
The product is developed by a small senior UK team under direct founder leadership — mobile, backend, signal processing, design and quality. Movement logic sits too close to clinical safety to outsource. That protects clinical accuracy, IP ownership, data governance and regulatory readiness.
Reroute is positioned as a Class IIa software medical device with a deliberate path toward UKCA marking, DTAC compliance and NICE alignment. Post-market surveillance and an ISO 13485-aligned quality system are part of the build, not a retrofit.
We don't pitch full deployment. We propose tightly scoped pilots with named clinicians and defined cohorts — early-stage Parkinson's with gait freezing, FND with functional gait disturbance — against predefined outcome measures: adherence, symptom frequency, clinician-reported usability.
The same underlying engine extends to tremor, tics and upper-limb rehabilitation. But breadth comes only after deep clinical value is demonstrated in one condition. Credibility first; platform second.
Neurological conditions place long-term pressure on the NHS, reduce labour-market participation and drive repeated use of outpatient, community and urgent care. The UK combines acute clinical need with the system structure, regulatory clarity and research depth needed to prove a digital therapeutic properly — and then scale it.
Reroute is designed around infrastructure the UK population already has — not hardware it must buy.
Parkinson's affects an estimated 153,000 people in the UK, rising toward 172,000 by 2030. FND accounts for roughly 16% of outpatient neurology consultations. Demand for rehabilitation far exceeds clinical capacity.
A single, coordinated health system with defined care pathways and national procurement — and an active strategy to prioritise digitally enabled, remote and community-based care.
UKCA classification, DTAC, DCB0129/DCB0160 clinical safety and NICE evaluation give a demanding but legible path. Clearing it is a moat, not just a cost.
World-class neurology and neurorehabilitation research centres, and an established culture of evidence-based commissioning to validate against.
Near-universal smartphone ownership makes a hardware-free therapeutic deployable across urban and rural populations at low marginal cost.
Shortages in neurology, physiotherapy and community rehab mean the system must extend specialist care without proportionally growing headcount. That is precisely what Reroute does.
Rhythm, attention and habit are unusually well matched to these conditions. We begin where the fit is strongest.
Gait freezing and festination rarely happen in the consulting room. They happen at kerbs, in doorways, in crowds. Reroute detects the change in gait pattern as it emerges and delivers adaptive rhythmic cueing in the moment — extending the external-cueing effect that is well established clinically, but making it continuous, responsive and available wherever the patient is.
In FND, movement often normalises when conscious attention shifts away from it. This is the clearest white space in the market: FND is common, disabling and increasingly recognised, yet poorly served by existing digital products. Reroute operationalises attention diversion continuously and outside the clinic — using task-driven game layers to redirect focus at exactly the moments symptoms intrude.
Recovery continues long after discharge, but structured support usually does not. Passive sensing gives the rehabilitation team objective visibility of movement quality and volume at home, while rhythmic cueing and task layers support repetition-based motor relearning between appointments.
Fatigue and movement inefficiency are hard to capture in a snapshot appointment. Longitudinal, passive real-world data reveals patterns of exertion and decline that patient recall cannot, supporting more precise pacing strategies and earlier intervention.
people in the UK living with Parkinson's — rising toward 172,000 by 2030
of outpatient neurology consultations accounted for by FND
additional devices required — Reroute runs on the phone in the patient's pocket
from discovery to a pilot-ready MVP, built in-house in the UK
Build the minimum viable clinical product across a phased six-month cycle. Stand up the quality management system, pursue DTAC and UKCA readiness, and run tightly scoped clinical pilots with named NHS clinicians.
Move from pilots to active institutional accounts, embed use across NHS regions and integrated care systems, and publish outcomes that make the case for pathway integration rather than optional add-on status.
Enter the United States through anchor provider organisations and academic medical centres, then Germany and Japan — sequenced to reuse the clinical evidence base rather than rebuild it.
We are speaking with neurologists, physiotherapists, movement disorder specialists, NHS digital and clinical governance leads, and partners who want to see rehabilitation extend beyond the appointment. If that's you, we'd like to hear from you.